Teriparatide therapy was found to be Effective for medicatio
A Research was done to integrate the data published on the effect of teriparatide (TPTD) therapy on cases of medication-related osteonecrosis of the jaws (MRONJ) into a comprehensive analysis of clinical features.

An electronic search was undertaken in 6 databases. Descriptive analysis of clinicodemographic data of MRONJ were carried out. Poisson regression was also run to evaluate predictors of total resolution of MRONJ treated with TPTD.

--26 publications comprising 111 cases were included. Most reported cases affected female individuals with a mean age of 76.54 years.

--Osteoporosis represented the main reason for using antiresorptive drugs, with bisphosphonates as the most frequently reported. Comorbidities were commonly present.

--The most related trigger factor of MRONJ was dental extraction. Mandible was the most commonly affected site, with a mean evolution time of 5 months. MRONJ stage 2 was the most prevalent.

--Regarding TPTD treatment, in 45.1% cases, TPTD was used alone, with the total resolution being observed in 59.5% of the individuals.

--Associated therapy (54.9%) included surgery, antibiotic therapy, and laser therapy. Mean follow-up was 8.7 months.

--Poisson regression demonstrated that individuals with MRONJ stage 1 were 1.21 times more likely to present total resolution of osteonecrosis than individuals with MRONJ stage 3.

--Individuals who had undergone treatment with TPTD in association with another therapeutic modality were 1.21 times more likely to present total resolution of osteonecrosis than those who had undergone treatment with TPTD alone.

Finally, TPTD in combination with another medication, particularly antibiotic therapy, should be considered a viable MRONJ treatment option.

Source: https://link.springer.com/article/10.1007/s00198-021-06078-z